摘要
【目的】通过研究乙酰肝素酶(HPA)含量与微淋巴管密度的关系,探讨HPA在甲状腺乳头状癌淋巴结转移中的作用。【方法】采用Envision免疫组织化学两步法检测150例甲状腺乳头状癌和200例结节性甲状腺肿患者乙酰肝素酶、D2-40的表达情况,计算乙酰肝素酶平均光密度值与D2-40阳性标记的微淋巴管密度,分析乙酰肝素酶含量与微淋巴管密度间的关系,同时与结节性甲状腺肿患者微淋巴管密度和乙酰肝素酶含量分别进行比较。【结果】甲状腺乳头状癌患者微淋巴管密度和乙酰肝素酶含量明显高于结节性甲状腺肿患者(P<0.01),癌组织乙酰肝素酶含量与微淋巴管密度呈正相关关系(P<0.01)。【结论】甲状腺乳头状癌患者乙酰肝素酶与微淋巴管形成有密切关系,乙酰肝素酶可作为其临床疗效判断和新药研发的参考指标。
【Objective】By studying the relationship between heparanase(HPA)content and micro-lymphatic vessel density,we investigated the effect of heparanase on lymphatic metastasis of papillary thyroid cancer.【Methods】Heparanase and D2-40 levels were detected in 150 specimens of papillary thyroid cancer and 200 of nodular goiter by Envision immunohistochemistry.Micro-lymphatic vessels were identified immunohistochemically as D2-40-positive.The relationship between micro-lymphatic vessel density and heparanase levels was analyzed.【Results】Micro-lymphatic vessel density and heparanase levels in patients with papillary thyroid cancer were significantly higher than those in nodular goiter patients(P <0.01).The content of heparanase was positively related with the micro-lymphatic vessel density in tumor tissues(P<0.01).【Conclusion】The metastasis process of papillary thyroid cancer is associated with heparanase levels.Heparanase may be a potential marker on the therapeutic effect and new drugs for papillary thyroid cancer in the future.
出处
《广西科学》
CAS
2015年第1期44-47,共4页
Guangxi Sciences
基金
中国医大盛京医院科学研究基金项目(M996)
国家自然科学基金项目(81072182)资助
关键词
甲状腺癌
淋巴结转移微淋巴管
乙酰肝素酶
thyroid carcinoma,lymph node metastasis,micro-lymphatic vessel,heparanase
